Guhan Pharmaceutical Group Co., Ltd. (SHE:000590)
China · Delayed Price · Currency is CNY 9.10
-0.04 (-0.44%)
Sep 30, 2026, 3:04 PM CST
SHE:000590 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 329.41 | 337.67 | 343.21 | 404.65 | 350.53 | 300.77 |
Revenue Growth | -2.83% | -1.61% | -15.18% | 15.44% | 16.54% | 9.34% |
Gross Profit Gross Profit Growth | 142.58 | 149.22 | 159.87 | 211.24 | 178.31 | 166.09 |
Operating Income Operating Income Growth | -17.67 | -25.63 | -25.7 | 14.3 | 12.13 | 25.87 |
Net Income Net Income Growth | -48.32 | -50.52 | -125.47 | 25.25 | 18.11 | 35.44 |
Earnings Per Share EPS Growth | -0.20 | -0.21 | -0.52 | 0.11 | 0.08 | 0.15 |
EPS Growth | - | - | - | 39.42% | -48.91% | 55.96% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business Active Pharmaceutical Ingredient (API) Manufacturing and Sales Business Growth | 3.73 |
Pharmaceutical and Health Product Manufacturing and Sales Business Pharmaceutical and Health Product Manufacturing and Sales Business Growth | 523.14 |
Offset of Business Segment Offset of Business Segment Growth | -206.82 |
Other Operations Other Operations Growth | 17.63 |
Total Total Growth | 337.67 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 141.13 | 177.71 | 177.29 | 189.77 | 260.53 | 325.83 |
Total Debt Total Debt Growth | 69.28 | 71.97 | 98.42 | 95.43 | 133.79 | 8.58 |
Net Cash (Debt) Net Cash Growth | 71.84 | 105.74 | 78.87 | 94.34 | 126.74 | 317.24 |
Net Cash Growth | -12.83% | 34.07% | -16.40% | -25.56% | -60.05% | -6.13% |
Net Cash Per Share Net Cash Per Share Growth | 0.30 | 0.44 | 0.33 | 0.39 | 0.53 | 1.32 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -24.19 | 28.96 | 17.39 | -29.39 | 54.47 | 25.2 |
Capital Expenditures CapEx Growth | -42.06 | -48.81 | -32.1 | -22.04 | -18.68 | -25.88 |
Free Cash Flow Free Cash Flow Growth | -66.25 | -19.85 | -14.71 | -51.43 | 35.79 | -0.68 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 43.28% | 44.19% | 46.58% | 52.20% | 50.87% | 55.22% |
Operating Margin | -5.37% | -7.59% | -7.49% | 3.53% | 3.46% | 8.60% |
Pretax Margin | -14.50% | -14.69% | -35.59% | 7.33% | 6.24% | 13.91% |
Profit Margin | -14.67% | -14.96% | -36.56% | 6.24% | 5.17% | 11.78% |
FCF Margin | -20.11% | -5.88% | -4.29% | -12.71% | 10.21% | -0.23% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 84.99 | 118.22 | 66.76 |
Forward PE | - | 91.43 | 91.43 | 91.43 | 91.43 | 91.43 |
P/FCF Ratio | - | - | - | - | 59.82 | - |
PS Ratio | 6.62 | 7.95 | 4.96 | 5.30 | 6.11 | 7.87 |